Market capitalization | $700.69m |
Enterprise Value | $2.05b |
PER (TTM) P/E ratio | 9.98 |
EV/FCF (TTM) EV/FCF | 218.07 |
EV/Sales (TTM) EV/Sales | 1.81 |
P/S ratio (TTM) P/S ratio | 0.62 |
P/B ratio (TTM) P/B ratio | negative |
Dividend yield | 4.94% |
Last dividend (FY23) | $0.60 |
As a free StocksGuide basic user, you can view the scores for all 6,954 shares worldwide.
4 Analysts have issued a Embecta forecast:
4 Analysts have issued a Embecta forecast:
Mar '24 |
+/-
%
|
||
Turnover | 287 287 |
4%
4%
|
|
Gross income | 184 184 |
3%
3%
|
|
EBITDA | 82 82 |
29%
29%
|
EBIT (operating result) EBIT | 72 72 |
29%
29%
|
Net profit | 29 29 |
106%
106%
|
Figures in millions USD.
If you wish, you can receive an e-mail every morning in time for breakfast containing all the stock news relevant to you.
Embecta Corp. engages in the provision of medical devices used in the treatment of diabetes. Its products include pen needles, syringes, and safety devices complemented by a digital application. The company was founded in 1924 and is headquartered in Parsippany, NJ.
Head office | United States |
CEO | Devdatt Kurdikar |
Employees | 2,200 |
Founded | 1924 |
Website | www.embecta.com |
StocksGuide is the ultimate tool for easily finding, analyzing and tracking stocks. Learn from successful investors and make informed investment decisions. We empower you to become a confident, independent investor.